Keywords: Nelfinavir, Breast cancer, Mouse model, HIV drug, Viracept, Roche, Johns Hopkins researchers

HIV drug nelfinavir shows efficacy in mouse models of HER2+ breast cancer

Article | 08 October 2012

Print This

The HIV protease inhibitor nelfinavir, marketed by Swiss drug major Roche as Viracept, can be used to treat HER2-positive ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in